More than half of patients with Ph-like ALL have CRLF2 rearrangements, and of those with such rearrangements, 50% have concurrent activating mutations of Janus kinases (JAK1, JAK2, and JAK3) [41,71]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.